inclusion criteria: * provision of signed and dated informed consent form * stated willingness to comply with all study procedures and availability for the duration of the study. * male or female, aged 18-85 * diagnosed with q-pcr confirmed infection with sars-cov-2 virus and admitted to the hospital. * receiving non-invasive respiratory support through a nasal cannula or a face mask. * ability to take oral medication and be willing to adhere to the tazemetostat regimen.

inclusion criteria: * provision of signed and dated informed consent form * stated willingness to comply with all study procedures and availability for the duration of the study. * male or female, aged 18-85 * diagnosed with q-pcr confirmed infection with sars-cov-2 virus and admitted to the hospital. * receiving non-invasive respiratory support through a nasal cannula or a face mask. * ability to take oral medication and be willing to adhere to the tazemetostat regimen.

inclusion criteria: - provision of signed and dated informed consent form - stated willingness to comply with all study procedures and availability for the duration of the study. - male or female, aged 18-85 - diagnosed with q-pcr confirmed infection with sars-cov-2 virus and admitted to the hospital. - receiving non-invasive respiratory support through a nasal cannula or a face mask. - ability to take oral medication and be willing to adhere to the tazemetostat regimen.

inclusion criteria: - provision of signed and dated informed consent form - stated willingness to comply with all study procedures and availability for the duration of the study. - male or female, aged 18-85 - diagnosed with q-pcr confirmed infection with sars-cov-2 virus and admitted to the hospital. - receiving non-invasive respiratory support through a nasal cannula or a face mask. - ability to take oral medication and be willing to adhere to the tazemetostat regimen.